Search Results - "Doger de Speville Uribe, Bernard"

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study by O'Malley, David M, Neffa, Maryna, Monk, Bradley J, Melkadze, Tamar, Huang, Marilyn, Kryzhanivska, Anna, Bulat, Iurie, Meniawy, Tarek M, Bagameri, Andrea, Wang, Edward W, Doger de Speville Uribe, Bernard, Hegg, Roberto, Ortuzar Feliu, Waldo, Ancukiewicz, Marek, Lugowska, Iwona

“…Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emerging as promising…”
Get full text

Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study by Yonemori, Kan, Boni, Valentina, Min, Kim Gun, Meniawy, Tarek M., Lombard, Janine, Kaufman, Peter A., Richardson, Debra L., Bender, Laura, Okera, Meena, Matsumoto, Koji, Giridhar, Karthik V., García-Sáenz, José Angel, Prenen, Hans, de Speville Uribe, Bernard Doger, Dizon, Don S., Garcia-Corbacho, Javier, Van Nieuwenhuysen, Els, Li, Yujia, Estrem, Shawn T., Nguyen, Bastien, Bacchion, Francesca, Ismail-Khan, Roohi, Jhaveri, Komal, Banda, Kalyan

“…Imlunestrant is a next-generation oral selective estrogen receptor degrader designed to deliver continuous estrogen receptor (ER) target inhibition. EMBER is a…”
Get full text

Abstract CT235: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumors by Gettinger, Scott, Kluger, Harriet, Schoenfeld, Adam, Betof-Warner, Allison, He, Kai, Sukari, Ammar, Doger de Speville Uribe, Bernard, Lee, Sylvia, Haefliger, Simon, Goldberg, Zelanna, Cacovean, Alex, Fiaz, Rana, Chen, Guang, Jagasia, Madan, Finckenstein, Friedrich Graf, Fardis, Maria, Jimeno, Antonio

“…Abstract Background TIL (especially CD8+ T cells) in the tumor microenvironment is associated with survival outcomes in many solid tumors, including melanoma…”
Get full text

Abstract PO1-26-02: Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models by Moreno, Crystal, Flores, Johnnie, Simonson, Alyssa, DeBoer, Maci, Banos, Natalia, III, Armando Diaz, Lynch, Morgan, Lund, Jim, Leykum, Leonora, Rouzbahan, Tahmi, Pedregal, Manuel, Papadopoulos, Kyriakos P., Lang, Amy, Rosenthal, Arthur, Rasco, Drew, Rodriguez, Gladys, Rodriguez, Luis, Lakhani, Nehal, Beeram, Muralidhar, Patnaik, Amita, De Miguel, Maria, Drengler, Ronald, Abbate, Steven, Uribe, Bernard Doger de Speville, Wick, Michael

“…Abstract EV is a Nectin-4 targeting antibody-drug conjugate (ADC) with an MMAE payload, recently approved for treatment of bladder cancer patients. To better…”
Get full text

Abstract CT110: Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors by Gambardella, Valentina, Ong, Michael, Ruiz, Maria Esperanza Rodriguez, Machiels, Jean-Pascal, de Sanmamed, Miguel Fernandez, Tabernero, Josep Maria, Spreafico, Anna, Renouf, Daniel J, Luen, Stephen J, Galot, Rachel, de Speville Uribe, Bernard Doger, Aller, Emiliano Calvo, Naing, Aung, Curdt, Samira, Rossmann, Eva, Tanos, Tamara, Smart, Kevin, Amann, Maria, Xie, Yuying, Schnetzler, Gabriel, Boetsch, Christophe, Karanikas, Vaios, Kolben, Theresa, Xu, Linxinyu, Rohrberg, Kristoffer S

“…Abstract Background RG6292 is the first anti-human CD25 antibody developed to specifically deplete human Tregs while preserving IL-2R STAT5 signaling and Teff…”
Get full text

Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01) by Piccart, Martine, Hennequin, Audrey, Borrego, Manuel Ruiz, Escrivá-de-Romani, Santiago, Williams, Anja, Rodríguez, Begoña Jiménez, Conte, Gianluca Del, Howell, Sacha J., Palleschi, Michela, Simonelli, Matteo, Duhoux, Francois P., Tosi, Diego, Uribe, Bernard Doger de Speville, Gilarranz, Yolanda Jerez, Tassone, Pierfrancesco, Curigliano, Giuseppe, Waters, Simon, Aftimos, Philippe, Wildiers, Hans, Scartoni, Simona, Vallespir, Bartomeu Piza, Shankaraiah, Ram Charan, Grzegorzewski, Krzysztof, Habboubi, Nassir

“…Abstract Background: MEN1611 (MEN) is an oral PI3K inhibitor active on the p110α mutant and wild type, β and γ isoforms, while sparing the δ. B-PRECISE-01 is…”
Get full text

Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry by Manz, Christopher, Ruiz-Hispán, Eva, Hernandez Guerrero, Tatiana, Doger de Spéville Uribe, Bernard, Morillo, Daniel, Mahillo, Ignacio, Garcia-Foncillas, Jesus, Ferrell, William J., Barnett, Ian J, Schriver, Emily R, Parikh, Ravi Bharat, Moreno, Victor

“…12012 Background: Performance status (PS) assessment is critical for clinical trial eligibility assessment and treatment selection. However, PS is based on the…”
Get full text

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A by Thomas, Sajeve Samuel, Gogas, Helen, Hong, Young Ki, In, Gino Kim, Doger de Spéville Uribe, Bernard, Furness, Andrew J.S., García Castaño, Almudena, Haefliger, Simon, He, Kai, Medina, Theresa, Lawrence, Donald, Lee, Sylvia, Martin-Liberal, Juan, Graf Finckenstein, Friedrich, Gastman, Brian, Chou, Jeffrey, Fiaz, Rana, Catlett, Melissa, Chen, Guang, Terheyden, Patrick

“…9505 Background: Immune checkpoint inhibitors (ICI) are front-line standard-of-care treatment (tx) for advanced (unresectable or metastatic) melanoma. Despite…”
Get full text